AptarGroup, Inc.

NYSE:ATR

Medical - Instruments & Supplies

Healthcare
$141.67 +0.55%

+$0.66 today

Market cap
$8.98B
Beta
0.40
P/E (TTM)
20.0
EPS (TTM)
$6.04
Dividend yield
1.57%
52W Low $103.23High $164.28

Volume 0.34M

Average 0.51M

ATR Other Financing Activities

Financing cash flows not reported separately.

AptarGroup, Inc.NYSE: ATR

Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026

Other financing activities turns negative

Q2 FY2026 other financing activities was -$1.53M, compared with $7.19M a year earlier. Trailing-twelve-month other financing activities was $7.93M.

Context

  • Other financing activities amounted to 0.0% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Other financing activities increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near -$1.53M or moves back toward the trailing-twelve-month quarterly average of $1.98M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.53M-129.8% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMJun 2026
$7.93M-78.9% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-121.3%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Other Financing Activities vs competitors

How ATR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -78.9% is the 4th highest of 6, against a peer median of +107.8%.
  • Other financing activities amounts to 0.2% of revenue for ATR, versus a peer median of 0.8%.
ATR Competitors
Other Financing Activities for ATR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$436.7M USD-3593.6%—13.1%
SLGNSilgan Holdings Inc.LTM Jun 2026$107.8M USD-200.4%—1.6%
AMCRAmcor plcLTM Jun 2026$98.46M USD+400.8%+17.8%0.4%
SONSonoco Products CompanyLTM Sep 2026$28.95M USD+715.8%-74.4%0.4%
STVNStevanato Group S.p.A.LTM Jun 2026€14.98M EUR——1.2%
ATRAptarGroup, Inc.LTM Jun 2026$7.93M USD-78.9%—0.2%
TRSTriMas CorporationLTM Mar 2026$280K USD+107.8%—0.0%
Peer median (excluding ATR) —+107.8%-28.3%0.8%

Competitors are the stored peer set for ATR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income243.64M239.56M284.18M374.18M392.79M
Depreciation & Amortization234.85M233.71M248.59M263.78M287.36M
Deferred Income Tax(14.36M)(12.11M)(19.88M)(21.41M)(11.69M)
Stock-Based Compensation38.87M40.94M41.29M47.65M0
Change in Working Capital(169.7M)(45M)5.75M(32.26M)(125.45M)
Accounts Receivables(123.25M)(27.94M)15.43M(18.08M)(73.89M)
Inventory(79.96M)(60.35M)(10.64M)21.9M(10.65M)
Accounts Payables52.31M55.1M14.6M(23.71M)(18.27M)
Other Working Capital(18.79M)(11.8M)(13.64M)(12.38M)(22.64M)
Other Non-Cash Items30.13M21.52M15.31M11.47M26.99M
Operating Cash Flow363.44M478.62M575.24M643.41M570M
Capital Expenditures(307.94M)(315.62M)(318.4M)(294.19M)(270.42M)
Acquisitions (Net)(148.42M)(4.1M)(16.57M)0(55.87M)
Purchases of Investments(7.37M)00(101.3M)(8.66M)
Sales of Investments2.43M2.34M5.6M05.77M
Other Investing Activities4.05M21.74M4.91M(1.23M)3.56M
Investing Cash Flow(457.24M)(295.64M)(324.46M)(396.72M)(330.64M)
Debt Repayment36.95M4.99M(51.55M)(97.46M)388.64M
Common Stock Issued000018.89M
Common Stock Repurchased(78.15M)(92.13M)(47.55M)(68.64M)(365.01M)
Dividends Paid(98.51M)(99.46M)(103.68M)(114.06M)(120.78M)
Other Financing Activities58.19M24.5M31.23M54.81M0
Financing Cash Flow(81.52M)(162.1M)(171.55M)(225.34M)(78.26M)
Effect of Forex Changes(6.73M)(1.07M)2.19M(21.15M)16.98M
Net Change in Cash(182.05M)19.81M81.41M201K178.08M
Free Cash Flow55.51M163M256.84M349.22M299.58M

AptarGroup, Inc.

NYSE:ATR

Intrinsic Alpha fair value

Locked

Current Price

$141.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.